Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)
China
· Delayed Price · Currency is CNY 19.99
-0.56 (-2.73%)
May 9, 2025, 3:00 PM CST
SHA:688062 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Operating Revenue | 176.86 | 199.62 | 127.68 | 27.6 | 15.88 | 5.16 | Upgrade
|
| Other Revenue | 0.16 | 0.16 | 0.15 | 0.13 | 0.35 | 0.14 | Upgrade
|
| Revenue | 177.01 | 199.78 | 127.84 | 27.73 | 16.23 | 5.3 | Upgrade
|
| Revenue Growth (YoY) | -7.49% | 56.28% | 361.03% | 70.88% | 206.03% | -81.98% | Upgrade
|
| Cost of Revenue | 43.57 | 34.48 | 7.3 | 2.01 | 5.22 | 5.4 | Upgrade
|
| Gross Profit | 133.45 | 165.3 | 120.53 | 25.72 | 11 | -0.1 | Upgrade
|
| Selling, General & Admin | 408.68 | 405.2 | 368.36 | 267.62 | 189.16 | 87.08 | Upgrade
|
| Research & Development | 809.26 | 782.87 | 835.78 | 758.61 | 622.51 | 581.19 | Upgrade
|
| Other Operating Expenses | 11.88 | 4.42 | 3.8 | 1.88 | 0.8 | 0.93 | Upgrade
|
| Operating Expenses | 1,230 | 1,193 | 1,208 | 1,028 | 812.44 | 668.06 | Upgrade
|
| Operating Income | -1,097 | -1,027 | -1,087 | -1,002 | -801.44 | -668.16 | Upgrade
|
| Interest Expense | -64.28 | -57.78 | -13.35 | -10.3 | -6.41 | -1.04 | Upgrade
|
| Interest & Investment Income | 13.98 | 20.92 | 46.88 | 45.75 | 7.38 | 16.87 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.28 | 0.28 | -0.01 | 0.16 | -0.24 | -0.08 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.93 | -2.34 | -1.74 | -1.82 | 2.63 | -2.94 | Upgrade
|
| EBT Excluding Unusual Items | -1,151 | -1,066 | -1,056 | -968.59 | -798.07 | -655.35 | Upgrade
|
| Gain (Loss) on Sale of Investments | -5.25 | -3.73 | -4.69 | 1.08 | -0.23 | 1.09 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.11 | -0.11 | -0.01 | 0.33 | 2.06 | -0.01 | Upgrade
|
| Asset Writedown | 0.02 | - | -3.56 | - | - | - | Upgrade
|
| Other Unusual Items | 22.5 | 22.5 | 8.61 | 9.06 | 23.54 | 10.65 | Upgrade
|
| Pretax Income | -1,134 | -1,047 | -1,055 | -958.13 | -772.7 | -643.62 | Upgrade
|
| Income Tax Expense | -0.85 | -0.91 | 3.52 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -1,133 | -1,047 | -1,059 | -958.13 | -772.7 | -643.62 | Upgrade
|
| Minority Interest in Earnings | 2.82 | 2.65 | 5.38 | 2.89 | 3.11 | 1.08 | Upgrade
|
| Net Income | -1,130 | -1,044 | -1,053 | -955.23 | -769.59 | -642.55 | Upgrade
|
| Net Income to Common | -1,130 | -1,044 | -1,053 | -955.23 | -769.59 | -642.55 | Upgrade
|
| Shares Outstanding (Basic) | 399 | 400 | 399 | 391 | 299 | 284 | Upgrade
|
| Shares Outstanding (Diluted) | 399 | 400 | 399 | 391 | 299 | 284 | Upgrade
|
| Shares Change (YoY) | -0.08% | 0.24% | 1.93% | 30.74% | 5.32% | - | Upgrade
|
| EPS (Basic) | -2.83 | -2.61 | -2.64 | -2.44 | -2.57 | -2.26 | Upgrade
|
| EPS (Diluted) | -2.83 | -2.61 | -2.64 | -2.44 | -2.57 | -2.26 | Upgrade
|
| Free Cash Flow | -1,109 | -1,287 | -1,283 | -1,264 | -639.91 | -645.61 | Upgrade
|
| Free Cash Flow Per Share | -2.78 | -3.22 | -3.21 | -3.23 | -2.14 | -2.27 | Upgrade
|
| Gross Margin | 75.39% | 82.74% | 94.29% | 92.75% | 67.81% | -1.87% | Upgrade
|
| Operating Margin | -619.65% | -514.17% | -850.65% | -3615.06% | -4939.16% | -12601.66% | Upgrade
|
| Profit Margin | -638.36% | -522.53% | -824.05% | -3445.00% | -4742.85% | -12118.54% | Upgrade
|
| Free Cash Flow Margin | -626.51% | -643.96% | -1003.35% | -4559.01% | -3943.69% | -12176.27% | Upgrade
|
| EBITDA | -994.42 | -930.36 | -1,013 | -937.96 | -739.4 | -611.77 | Upgrade
|
| D&A For EBITDA | 102.46 | 96.85 | 74.43 | 64.43 | 62.04 | 56.39 | Upgrade
|
| EBIT | -1,097 | -1,027 | -1,087 | -1,002 | -801.44 | -668.16 | Upgrade
|
| Revenue as Reported | 177.01 | 199.78 | 127.84 | 27.73 | 16.23 | 5.3 | Upgrade
|
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.